Hyper Corporation Inc. (KOSDAQ: 065650)

Market Cap	137.83B
Revenue (ttm)	31.41B
Net Income (ttm)	-3.52B
Shares Out	106.68M
EPS (ttm)	-100.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,254,604
Average Volume	915,304
Open	1,265.00
Previous Close	1,292.00
Day's Range	1,235.00 - 1,317.00
52-Week Range	956.00 - 1,697.00
Beta	1.36
RSI	54.51
Earnings Date	Feb 21, 2025

About Hyper Corporation

Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and w...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 1997
• Employees: 33
• Stock Exchange: KOSDAQ
• Ticker Symbol: 065650

Financial Performance

In 2020, Hyper Corporation's revenue was 31.41 billion, an increase of 80.41% compared to the previous year's 17.41 billion. Losses were -3.52 billion, 97.9% more than in 2019.